Withholding the Introduction of Anti‐Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild‐Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)

BACKGROUND: Patients with RAS wild‐type (WT) nonresectable metastatic colorectal cancer (mCRC) may receive either bevacizumab or an anti‐epidermal growth factor receptor (EGFR) combined with first‐line, 5‐fluorouracil‐based chemotherapy. Without the RAS status information, the oncologist can either...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmieri, Lola‐Jade, Mineur, Laurent, Tougeron, David, Rousseau, Benoît, Granger, Victoire, Gornet, Jean‐Marc, Smith, Denis, Lievre, Astrid, Galais, Marie‐Pierre, Doat, Solene, Pernot, Simon, Bignon‐Bretagne, Anne‐Laure, Metges, Jean‐Philippe, Baba‐Hamed, Nabil, Michel, Pierre, Obled, Stéphane, Vitellius, Carole, Bouche, Olivier, Saban‐Roche, Léa, Buecher, Bruno, des Guetz, Gaëtan, Locher, Christophe, Trouilloud, Isabelle, Goujon, Gaël, Dior, Marie, Manfredi, Sylvain, Soularue, Emilie, Phelip, Jean‐Marc, Henriques, Julie, Vernery, Dewi, Coriat, Romain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011620/
https://www.ncbi.nlm.nih.gov/pubmed/32043796
http://dx.doi.org/10.1634/theoncologist.2019-0328

Ejemplares similares

Ejemplares similares